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Theuseofnatriureticpeptidesintheneonatalpopulationisemerging.B-typeNatriureticPeptide(BNP)andN-terminal-Pro-BNP
(NTpBNP) are used in the adult population to assess myocardial function and volume loading. Their role in prognosis following
cardiac surgery has also been identiﬁed. In preterm infants NTpBNP is becoming increasingly recognised as a potential screening
tool for patent ductus arteriosus (PDA), and a marker for myocardial performance. In addition, NTpBNP may provide prognostic
information in preterm infants and term infants with congenital diaphragmatic hernia (CDH). In this paper, the role of NTpBNP
in the preterm population will be discussed.
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1.Introduction
B-type Natriuretic Peptide (BNP) is a 32-amino acid ring
structure coded by a sequence on chromosome 1. BNP acts
on a cyclic guanosine monophosphate (cGMP) coupled rec-
eptor via a transmembrane domain [1] .T h ev e n t r i c l e so f
the heart are the main site of BNP synthesis and release
in response to volume loading, pressure loading, and
ventricular stress. BNP causes diuresis, natriuresis, arterial
and venous vasodilatation, and antagonises the renin-
angiotensin system. The net eﬀect is a reduction of intravas-
cular volume, ventricular preload and afterload. The ring
structure must remain intact to ensure receptor binding to
natriuretic peptide receptors A and B (NPR-A/B). BNP is
excreted following cleavage by membrane bound neutral
peptidase found in the kidneys and vascular tree. NPR-C
also clears it from the blood by binding, endocytosis, and
lysosomal degradation [2]. N-terminal-Pro-BNP (NTpBNP)
is the inactive by-product of BNP resulting from the cleavage
of the parent peptide Pro-BNP. Both are released into
the circulation but no function has been associated with
NTpBNP. BNP has a short half-life of 20 minutes and is
unstable at room temperature. NTpBNP has a longer half-
life of compared to 60 to 120 and is stable under a range
of storage conditions. There are multiple kits available for
BNP measurements. This has led to discrepancies in cut
oﬀ levels across studies used for assessing BNPs prognostic
and haemodynamic assign properties. On the other hand,
available kits used for NTpBNP measurement are limited
in number. This may allow more comparisons to be made
across studies, thereby rendering it more suitable than BNP
for routine clinical monitoring [3].
2.ClinicalRoleofNatriureticPeptides
BNP and NTpBNP are good screening tools, detecting
chronic ventricular dysfunction in adults, with sensitivities
and speciﬁcities surpassing clinical and radiological methods
[4]. BNP and NTpBNP are useful in the diagnosis of
congestive heart failure in dyspnoeic patients presenting to
the emergency department [5]. In addition, these markers
facilitate the screening, treatment response, and prognosis
of asymptomatic patients with subclinical Left Ventricular
dysfunction [6–8].
BNP and NTpBNP levels are elevated in children with
heart disease causing ventricular pressure and volume load-
ing [9, 10]. In addition, plasma BNP correlates closely to
shunt volume in left-to-right cardiac lesions, increasing with
decreasing left ventricular ejection fraction, and positively2 International Journal of Pediatrics
correlating with increasing right ventricular systolic pres-
sures [11]. The levels can also reﬂect functional capacity
in children with congestive heart failure [9]. In children
with dilated cardiomyopathy NTpBNP is a good marker
for persistent left ventricular dysfunction with levels nor-
malising in children whose echocardiograms recover [12].
Among infants with respiratory distress, plasma NTpBNP
measurement can diﬀerentiate between acute heart failure
and lung disease and can be used to monitor response to
treatment [13]. Elevated preoperative NTpBNP in children
undergoing open heart surgery is linked with complicated
postoperative outcome [14]. NTpBNP is used preoperatively
to predict the development of postoperative low cardiac
output syndrome (LCOS) [15]. BNP levels tend to be
higher in children receiving long-term immunosuppressive
treatment post liver transplant compared to healthy controls
despite the lack of echocardiographic evidence of cardiac
compromisesuggesting thatBNP levelsmay identify patients
with early cardiac damage [16].
Limited data have demonstrated the potential beneﬁt
of these peptides as markers of cyanotic and obstructive
lesions. Cowley et al. demonstrated a signiﬁcant, correlation
between left ventricle to aorta gradient and BNP levels
[17]. NTpBNP has also been used to monitor response to
valve replacement in patients with aortic stenosis [18]. In a
recent study, Hopkins et al. found higher levels of NTpBNP
in 10 adult patients with cyanotic heart disease (including
Eisenmenger’s syndrome) despite the lack of ventricular
pressure loading [19].
3. Application of NTpBNP in Neonates
BNP and NTpBNP levels surge at birth to reach a plateau on
days 3 to 4, followed by a steady fall to reach a constant level
in infancy[20]. This surgeis probablymultifactorial but may
be due to the loss of the placental low pressure system and
exposure to the initially suprasystemic pulmonary pressures
subjecting the ventricle to greater volume and pressure
loading. Furthermore, the placenta plays a role in clearance
of NPs and loss of this clearance system contributes to the
high level [21]. This surge in BNP levels at birth may play
a regulatory role in the haemodynamic changes associated
with transition to extra-uterine life. Renal maturation, a
rise in systemic vascular resistance and a fall of pulmonary
pressures explain the subsequent fall in peptide levels.
There is a paucity of normative values of NTpBNP in
neonates (Table 1). Reference ranges quoted in the literature
vary according to the timing of the test, the kits used, and the
population investigated [22]. Most quoted reference ranges
are for term healthy neonates and therefore do not represent
the intensive care population. NTpBNP is not thought to
cross the placenta and therefore any variation in neonates
must be explained intrinsically [23].
4. Inﬂuence of Antenatal and Postnatal Events
on NTpBNP Levels inPretermInfants
The use of NTpBNP in assessing the haemodynamic status
of preterm infants is gaining interest. NTpBNP is released
in equimolar amounts to BNP from the myocardium. Its
levels however are higher and remain in the blood stream
f o rl o n g e rd u et od i ﬀering half-life and clearance [24]. Levels
of NTpBNP in the early preterm period were assessed in
a study of 80 preterm infants with a median gestation of
28 [IQR 26.1–29.5] weeks and median birth weight of 1.06
[IQR 0.87–1.21]kg. At 12 hours of life all infants had a
PDA with low velocity left to right shunting. The median
NTpBNP value for the cohort was 1273pmol/L with an
interquartile range (IQR) of 664–2798pmol/L and a range of
98–10700pmol/L. The inﬂuence of antenatal and postnatal
f a c t o r so nN T p B N Pl e v e l si si l l u s t r a t e di nTable 2.I n f a n t s
withRDShadsigniﬁcantlyhigherNTpBNPvaluescompared
to controls [25]. When adjusted for RDS, gestation and
birth weight had no impact on NTpBNP. The premature
neonatal heart is distinguished from that of older infants
by several unique characteristics. The neonatal myocardium
has a higher water concentration and a greater proportion
of “stiﬀ” collagen resulting in a noncompliant ventricle and
diastolic dysfunction resulting in relatively poor ventricular
ﬁlling [26]. The preterm myocardium cannot therefore
respond to stress caused by the rise in afterload following the
loss of the low pressure system of the placenta. This problem
is further compounded by any potential stressors such as
hypoxia, anaemia and, mechanical ventilation which reduces
venous return and cause pressure on the myocardium
preventing eﬀective contraction [27]. This may explain the
higher values of NTpBNP seen in preterm infants compared
to term infants.
At 12 hours of life, there is a signiﬁcant negative corre-
lation between NTpBNP and echocardiographic markers of
left ventricular function including mean velocity of circum-
ferential ﬁbre shortening (mVcfs) (r =− 0.32, P = .02),
and shortening fraction (r =− 0.26, P = .03). Interestingly,
there is no correlation between NTpBNP and left atrial to
aortic root ratio (LA : Ao) or the diameter the PDA at
12 hours of life (r =− 0.14, P = .24). Echocardiographic
assessment of the eﬀect of ductal shunting on the systemic
andpulmonarycirculationssuggeststhatshuntingacrossthe
PDA is not signiﬁcant at this early stage due to the relatively
high pulmonary vascular resistance [28].
NTpBNP levels were assessed in the same population of
infants at 48 hours of age [29]. Forty ﬁve infants developed
a PDA compared to 35 infants who closed their ducts
spontaneously beyond 48 hours. Infants with a PDA had
a signiﬁcantly higher NTpBNP levels compared to controls
(6059 versus 740pmol/L, P<. 001). There is a signiﬁcant
strong correlation between NTpBNP and LA : Ao (r =
0.49, P ≤ .001), PDA diameter (r = 0.54, P = .001).
NTpBNP provided information regarding the eﬀects of the
PDAonpulmonaryovercirculation,representedbyapositive
correlation between levels and a rising left ventricular output
(LVO) (r = 0.31, P = .006) and an increasing mitral valve
inﬂow signal (r = 0.34, P = .007) assessed by echocardiog-
raphy. In addition, NTpBNP provides information regarding
systemic hypoperfusion. This was represented by a negative
correlation with descending aortic end diastolic velocity (r =
−0.58, P = .001), and celiac artery blood ﬂow (r =− 0.41,
P = .001). A Receiver operating characteristics curve (ROC)International Journal of Pediatrics 3
Table 1: Reference ranges for NTpBNP.
Study N Age range/source Kit NTpBNP levels
Mir et al. [20] 153 Day 1 Biomedica Mean: 641pmol/L
Venous/cord Range: 254–1272
Mir et al. [20] 153 Day 3 Biomedica Mean: 246
Venous/cord Range: 110–430pmol/L
Nir et al. [22] 43 0–2 days Elecsys Median: 376pmol/L
1010/2010 Range: 30–1560pmol/L
Bar-Oz et al. [23] 122 Day 1 Elecsys Mean: 68pmol/L
Cord blood 1010/2010 SD: 41pmol/L
Bar-Oz et al. [23] 33 Day 1 Elecsys Mean: 359pmol/L
Plasma 1010/2010 SD: 210pmol/L
Schwachtgen et al. [30] 62 Day 1 ECLIA Mean: 97pmol/L
Cord blood Roche Range: 33–306pmol/L
Hammerer-Lercher et al. [31] 42 Day 1 Elecsys Mean: 65pmol/L
Cord blood 1010 IQR: 49–98pmol/L
Bakker et al. [32] 67 32–42wk Elecsys Mean: 79.5pmol/L
Cord blood 2010 SD: 42.9pmol/L
Rauh and Koch [33]1 3 <1 month Elecsys Range: 132–913pmol/L
Plasma
Soldin et al. [34]4 0 ♂ <31Days Dade RxL 97.5th percentile: 3352pmol/L
Plasma Dimension
Soldin et al. [34]5 3 ♀ <31days Dade RxL 97.5th percentile: 4940pmol/L
Plasma Dimension
EL-Khuﬀash et al. [25] 80 12 hours of life Elecsys Mean: 1273pmol/L
<1500 grams 2010 IQR: 664–2798 range: 94–10700
Table 2: Inﬂuence of antenatal and factors on NTpBNP levels at 12
hours (Mann Whitney U test was used to compare medians).
Grouping variable Group NTpBNP (pmol/L)
Median P-value
Sex Boy 1273 .32
Girl 1454
Chorioamnionitis No 1199 .07
Yes 2248
Steroids None 1586 .42
Partial 840
Full 1462
Delivery SVD 1275 .60
CS 1222
Inotrope use No 1368 .83
Yes 1269
RDS No 815 .04
Yes 1391
was constructed to evaluate the bioassays’ detection of a
PDA conﬁrmed by echocardiography, with an area under
the curve (AUC) of 0.88 (95%CI 0.79–0.96) for NTpBNP.
At 4000pmol/L, NTpBNP had a sensitivity of 70% and a
speciﬁcity of 89% for the presence of a PDA [35].
The association between NTpBNP and PDA levels was
replicated in three other studies (Table 3). The cut-oﬀ
levels for the detection of a PDA vary by 2- to 3-fold
amongst the studies (Table 3). This may be due to the
diﬀerentpopulationsstudiedandthediﬀeringdeﬁnitionofa
haemodynamically signiﬁcant PDA across the studies. In the
three other studies, no echocardiographic assessments were
carried out to assess systemic hypoperfusion and pulmonary
circulation [36–38]. They relied solely on ductal diameter
and LA : Ao ratio. These markers in isolation do not give
an accurate assessment of the degree of ductal steal and
pulmonary over circulations. Therefore, the use of a lower
threshold may over diagnose a signiﬁcant PDA [28, 29].
Nuntnarumit et al. found a stronger correlation with LA : Ao
(r = 0.77, P = .001). The lack of eﬀect of gestation and
birthw eightonNTpBNPlev elsw er ealsodemonstrat ed[36].
Interestingly, Farombi-Oghuvbu et al. found a weak negative
correlation between gestational age and NTpBNP levels on
day 1 (r2 = 0.16, P = .02). The lack of inﬂuence of antenatal
and postnatal factors illustrated in Table 2 was replicated in
their study [37]. They showed a lack of association between
NTpBNP levels and prolonged rupture of membranes, the
use of inotropes, and early sepsis. They did ﬁnd however
that there was a weak association between gestational age
andNTpBNPwiththelevelsbeinghigherinmorepremature
infants (β =− 0.495, P = .013).
NTpBNP may have a role in monitoring treatment
response. In our population, following successful PDA
treatment, NTpBNP levels fell signiﬁcantly to levels similar
to controls (from 6059 to 998pmol/L, P<. 001). In the4 International Journal of Pediatrics
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control group NTpBNP levels decreased signiﬁcantly from
740pmol/L at 48 hours to 272pmol/L on Day 7. Nuntnaru-
mit et al. showed that infants who do not respond to the ini-
tialcourseoftreatmenthavepersistentlyhighNTpBNPlevels
compared to responders (2337 versus 353pmol/L, P = .007).
The ability of NTpBNP to predict the presence of
a PDA seems to surpass that of BNP. There is a wide
variation in BNP levels associated with a signiﬁcant PDA
ranging from 70–1110pg/mL despite using the same assay
[39–42]. This may be explained by the shorter half-life
and instability of BNP described earlier. In addition, the
correlation of NTpBNP with the echocardiographic markers
of PDA signiﬁcance is more consistent. Flynn et al. showed
that BNP had a weaker correlation with echocardiographic
markers of PDA signiﬁcance including ductal size (r = 0.62),
increased pulmonary ﬂow (r = 0.63), and increased steal
(retrogradediastolicﬂow)inthedescendingaorta(DAo)and
the superior mesenteric artery (SMA) (r = 0.54 and 0.41).
Therewasapoorcorrelationbetweenleftatrialtoaorticratio
(LA : Ao ratio) and BNP levels (r = 0.33) in this study
[43]. However, Choi BM et al. revealed a stronger correlation
(r = 0.73) [39].
NTpBNP may be an ideal screening tool for a PDA due
to relatively close cut-oﬀ levels of NTpBNP for diagnosis
a PDA across the studies conducted thus far, the strong
correlation with echo markers of PDA signiﬁcance, and
the lack of inﬂuence of antenatal and postnatal factors on
the levels. In addition, the levels fall signiﬁcantly following
successful treatment and persist in nonresponders. This
obviates the need for repeated echocardiograms to assess
treatment success.
5. NTpBNP and Outcome
The ability of NTpBNP to predict short-term outcomes in
preterm infants with a PDA was assessed by El-Khuﬀash et
al. [29]. In the study described in the previous section, the
PDA group was subdivided into infants with a poor outcome
(grade III/IV IVH, death or both, n = 20) and infants
without complications (n = 25). The poor outcome group
had a signiﬁcantly lower gestation and birth weights. There
were no diﬀerences in the antenatal characteristics between
the two groups. Infants in the poor outcome group had a
signiﬁcantly higher NTpBNP levels at 48 hours compared to
infants without PDA-associated complications (9284pmol/L
[5013–16911] versus 5121pmol/L [2324–6202], P = .008).
The AUC for NTpBNP’s ability to predict severe IVH and/or
death as a complication of a PDA is 0.84 (95% CI 0.72 –
0.96, P ≤ .001). A level of 5500pmol/L has a sensitivity
of 80% and a speciﬁcity of 80%. Only one infant in the
Spontaneous PDA closure group died before discharge. The
12- and 48-hour NTpBNP levels were 2023pmol/L and
6605pmol/L respectively. NTpBNP may be an independent
marker of poor neonatal short-term outcome irrespective of
P D Ap r e s e n c e( 2 9 ) .
GagliardiLetal.assessedthediscriminatoryabilityofthe
clinicalriskindexforbabies(CRIBs),CRIB-II,andSNAPPE-
II in detecting death before discharge in 720 preterm infants
[44]. Following the exclusion of babies weighing 400–499g
(n = 15), the AUCs for CRIB, CRIB-II, and SNAPPE-
II were 0.898, 0.905, and 0.835, respectively. These results
were comparable to the AUCs for NTpBNP and death in
this cohort. NTpBNP may prove to be a useful adjunct to
clinicalandechocardiographicPDAstagingsystemproposed
by McNamara et al. [45]. Medical therapy for PDA has
well recognised adverse eﬀects and neither prophylaxis nor
treatment on the basis of clinical and echocardiographic
signs have been shown to improve long-term outcomes.
Accurately identifying infants with PDA who are at highest
risk of poor outcome using NTpBNP may allow more
successful trials of targeted medical therapy of PDA.
6. Other Applicationsof NTpBNP
Pulmonary vascular resistance may remain elevated during
the neonatal period leading to diﬃculties in oxygenation and
resulting in pulmonary hypertension (PHT). Echocardiog-
raphy is required to distinguish PHT from other respiratory
and cardiac disorders by demonstrating suprasystemic pul-
monary vascular pressures. In a study of 28 term infants,
Baptista et al. showed a signiﬁcantly higher NTpBNP level
in infants with PHT secondary to congenital diaphragmatic
hernia (CHD) compared to age and weight matched controls
(1563 versus 591pmol/L, P<. 05). There was a good
correlation with right ventricular mean pressure (r = 0.45,
P = .03) and RV Tei index. This measurement is a combined
myocardial performance index (isovolumic contraction time
plus isovolumic relaxation time divided by ejection time)
(r =− 0.46, P = .02). In addition, the prognostic properties
ofNTpBNParedemonstratedinthistrial.Nineinfantsinthe
CHD group died before discharge. NTpBNP was higher in
the nonsurvivors (2679 versus 737pmol/L, P = .009). A level
of 1360pmol/L had a 100% sensitivity and 67% speciﬁcity
for identifying these infants.
Plasma BNP increases in animal models with induced
endotoxaemia and the proinﬂammatory cytokine inter
leukin-6 (IL-6) has been linked with BNP production.
Therefore, the rise of BNP may not be solely due to
ventricular overloading. In neonatal rat cardiac myocytes,
transcriptional activation of the BNP gene was initiated by
lipopolysaccharide (LPS) suggesting that elevated BNP levels
under endotoxaemic conditions are partially mediated by
LPS [46]. In patients with severe sepsis or septic shock, BNP
and NTpBNP values are highly elevated [47, 48] and, despite
signiﬁcant hemodynamic diﬀerences, comparable with those
found in acute heart failure in adult patients. It remains to
be determined how elevations of natriuretic peptide levels
are linked to inﬂammation and sepsis-associated myocardial
dysfunction [37, 48]. NTpBNP may also serve as useful
laboratory marker to predict survival in patients presenting
with severe sepsis [49]. Additionally, NTpBNP seems to be
an early predictor of myocardial dysfunction in patients with
septic shock [50]. NTpBNP may serve as a marker of cardiac
dysfunction associated with sepsis in preterm neonates and
be a useful adjunct in the diagnosis of sepsis. In preterm
infants, NTpBNP rises in the presence of late onset sepsis6 International Journal of Pediatrics
without the presence of a PDA or ventricular dysfunction.
The interpretation of NTpBNP levels in the presence of a
PDA and sepsis warrants further study.
7. Conclusion
NTpBNPhasamajordiagnosticroleintheadultpopulation.
In children, NTpBNP serves as an indicator of cardiac
disease and may be used to monitor response to treatment.
The potential beneﬁt of these NTpBNP in neonatology
is immense. It has a role in PDA screening, treatment
response and may also oﬀer prognostic information. More
studies are needed to explore the possible roles of NTpBNP
in the management of sepsis and monitoring of cardiac
performance. These two possible confounding factors may
limit its reliability in the diagnosis of PDA and its response
to treatment.
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